Synlogic Inc (SYBX)

$1.46 +0.06 (4.29%)
Market Cap 17.08M
Revenue (ttm) 10,000.00
Net Income (ttm) -23.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233,600.01%
Debt to Equity Ratio 0.00
Volume 10,500
Avg Vol 55,830
Day's Range N/A - N/A
Shares Out 11.70M
Stochastic %K 32%
Beta 0.52
Analysts Hold
Price Target $1.00

Company Profile

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 659 2802
Address:
PO Box 30, Winchester, United States
WallStVisions
WallStVisions Jul. 20 at 3:11 AM
RSLS is a low-float biotech just waiting for the spark. It’s got structure, a merger catalyst, and no toxic overhead all under $1. Once the move starts, it could halt its way up the chart. Perfect storm forming quietly…. $SABS $SYBX $ACXP $SEEL
0 · Reply
AsymmetricVentures
AsymmetricVentures Jul. 18 at 5:51 PM
Cable Car Cap controlled 9+% of $MEIP as of their last 13F. With that Digital Treasury deal out of the way ... they can focus on $SYBX, where they own 4.5+% per their last 13F
0 · Reply
Chrissytina
Chrissytina Jul. 16 at 3:02 PM
$SYBX 138,124 volume 😳 that’s a lot for this company!
0 · Reply
jaydilks
jaydilks Jul. 16 at 2:25 PM
$DNA Old news release might have validity why $17 Mill Market Cap, $SYBX stock is suddenly off life support. My guess would be GOUT Therapeutic. I’d own DNA over SYBX because of the leverage DNA has in ownership and IP. (Speculation Alert). Take it with a grain of Salt. https://www.prnewswire.com/news-releases/synlogic-announces-synthetic-biotic-for-gout-developed-in-partnership-with-ginkgo-bioworks-301603915.html
2 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 4:06 PM
$SYBX DUE TO THIS!*
1 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 3:56 PM
$ALTO $SYBX !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 3:56 PM
$SYBX !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 10:31 AM
$ALTO working on something for u some what soon $SYBX need to change foew things on sybx side note timer issue
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 9 at 10:16 PM
$SYBX $SBFM making changes for u both
1 · Reply
Love_To_Learn
Love_To_Learn Jul. 9 at 4:18 PM
$SYBX will need to do something with u soon have sidelined u for quite a bit it tight for now
0 · Reply
Latest News on SYBX
Synlogic Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:35 PM EST - 10 months ago

Synlogic Reports Third Quarter 2024 Financial Results

Synlogic Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Synlogic Reports Second Quarter 2024 Financial Results

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024, 7:00 AM EDT - 1 year ago

Synlogic Reports First Quarter 2024 Financial Results

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Synlogic Adopts Limited Duration Stockholders Rights Plan

Feb 20, 2024, 12:15 PM EST - 1 year ago

Synlogic Adopts Limited Duration Stockholders Rights Plan

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Feb 8, 2024, 4:15 PM EST - 1 year ago

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Feb 2, 2024, 12:00 PM EST - 1 year ago

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Synlogic Provides Corporate Update and Outlook for 2024

Jan 4, 2024, 7:00 AM EST - 1 year ago

Synlogic Provides Corporate Update and Outlook for 2024

Synlogic Announces Contract with the Air Force Research Lab

Dec 27, 2023, 7:00 AM EST - 1 year ago

Synlogic Announces Contract with the Air Force Research Lab

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Dec 7, 2023, 7:00 AM EST - 1 year ago

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 1 year ago

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

Oct 3, 2023, 4:15 PM EDT - 2 years ago

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

Sep 29, 2023, 7:00 AM EDT - 2 years ago

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Sep 28, 2023, 11:15 AM EDT - 2 years ago

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Synlogic Announces Reverse Stock Split

Sep 27, 2023, 12:30 PM EDT - 2 years ago

Synlogic Announces Reverse Stock Split

Synlogic to Participate in Chardan's Genetic Medicines Conference

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Synlogic to Participate in Chardan's Genetic Medicines Conference

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

Sep 19, 2023, 11:00 AM EDT - 2 years ago

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

Jul 11, 2023, 7:00 AM EDT - 2 years ago

Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

Jun 28, 2023, 7:00 AM EDT - 2 years ago

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

Jun 27, 2023, 7:00 AM EDT - 2 years ago

Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

Jun 8, 2023, 6:45 AM EDT - 2 years ago

Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Jun 5, 2023, 6:45 AM EDT - 2 years ago

Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

May 24, 2023, 6:35 AM EDT - 2 years ago

Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Synlogic to Present at the Jefferies Global Healthcare Conference

May 23, 2023, 6:50 AM EDT - 2 years ago

Synlogic to Present at the Jefferies Global Healthcare Conference

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 6:50 AM EDT - 2 years ago

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

May 9, 2023, 6:50 AM EDT - 2 years ago

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

Mar 29, 2023, 6:40 AM EDT - 2 years ago

Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria

Mar 28, 2023, 6:52 AM EDT - 2 years ago

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Mar 20, 2023, 6:55 AM EDT - 2 years ago

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Mar 7, 2023, 6:57 AM EST - 2 years ago

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Synlogic Announces Participation in Upcoming Investor and Industry Conferences

Jan 24, 2023, 6:57 AM EST - 2 years ago

Synlogic Announces Participation in Upcoming Investor and Industry Conferences

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

Jan 19, 2023, 6:58 AM EST - 2 years ago

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

Synlogic Provides Corporate Update and Outlook for 2023

Jan 5, 2023, 6:58 AM EST - 2 years ago

Synlogic Provides Corporate Update and Outlook for 2023

Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

Jan 3, 2023, 6:58 AM EST - 2 years ago

Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Dec 15, 2022, 6:59 AM EST - 2 years ago

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Nov 30, 2022, 4:15 PM EST - 2 years ago

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 6:59 AM EST - 3 years ago

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

Oct 18, 2022, 6:59 AM EDT - 3 years ago

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

Aug 23, 2022, 7:00 AM EDT - 3 years ago

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 1:41 PM EDT - 3 years ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2022 Results - Earnings Call Transcript

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Aug 11, 2022, 7:05 AM EDT - 3 years ago

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

DNA

Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 11, 2022, 6:58 AM EDT - 3 years ago

Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Jul 12, 2022, 7:00 AM EDT - 3 years ago

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Synlogic Announces Appointment of General Counsel and Corporate Secretary

Jun 29, 2022, 7:00 AM EDT - 3 years ago

Synlogic Announces Appointment of General Counsel and Corporate Secretary

Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

Jun 28, 2022, 7:00 AM EDT - 3 years ago

Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

Jun 21, 2022, 7:00 AM EDT - 3 years ago

Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2022 Results - Earnings Call Transcript

May 12, 2022, 12:54 PM EDT - 3 years ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2022 Results - Earnings Call Transcript

Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022, 7:00 AM EDT - 3 years ago

Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

WallStVisions
WallStVisions Jul. 20 at 3:11 AM
RSLS is a low-float biotech just waiting for the spark. It’s got structure, a merger catalyst, and no toxic overhead all under $1. Once the move starts, it could halt its way up the chart. Perfect storm forming quietly…. $SABS $SYBX $ACXP $SEEL
0 · Reply
AsymmetricVentures
AsymmetricVentures Jul. 18 at 5:51 PM
Cable Car Cap controlled 9+% of $MEIP as of their last 13F. With that Digital Treasury deal out of the way ... they can focus on $SYBX, where they own 4.5+% per their last 13F
0 · Reply
Chrissytina
Chrissytina Jul. 16 at 3:02 PM
$SYBX 138,124 volume 😳 that’s a lot for this company!
0 · Reply
jaydilks
jaydilks Jul. 16 at 2:25 PM
$DNA Old news release might have validity why $17 Mill Market Cap, $SYBX stock is suddenly off life support. My guess would be GOUT Therapeutic. I’d own DNA over SYBX because of the leverage DNA has in ownership and IP. (Speculation Alert). Take it with a grain of Salt. https://www.prnewswire.com/news-releases/synlogic-announces-synthetic-biotic-for-gout-developed-in-partnership-with-ginkgo-bioworks-301603915.html
2 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 4:06 PM
$SYBX DUE TO THIS!*
1 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 3:56 PM
$ALTO $SYBX !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 3:56 PM
$SYBX !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 10:31 AM
$ALTO working on something for u some what soon $SYBX need to change foew things on sybx side note timer issue
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 9 at 10:16 PM
$SYBX $SBFM making changes for u both
1 · Reply
Love_To_Learn
Love_To_Learn Jul. 9 at 4:18 PM
$SYBX will need to do something with u soon have sidelined u for quite a bit it tight for now
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 25 at 10:27 AM
$SYBX u have an update pending timing is not good in general for market dynamics may need to delay temp on this
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 30 at 10:50 AM
$ONFO $SYBX need u 2 rest of week nect bunch of trading days overlap with beloved situation and iotr too many to post
0 · Reply
PenkeTrading
PenkeTrading Apr. 5 at 5:03 PM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Synlogic Inc. Is that bullish or bearish? $SYBX #Synlogic #RsiOversold #NASDAQ
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 27 at 12:23 PM
$SYBX Tough break for SYBX after dropping PKU trial. Biotech's brutal - one miss can tank everything. Watching closely for strategic moves. Might be a value play if they find a buyer. Lean team, cash runway looking thin. Synthetic Biotics platform still intriguing. excellent article: https://beyondspx.com/article/synlogic-inc-sybx-navigating-the-complexities-of-the-biotech-landscape
0 · Reply
Kaltycoon
Kaltycoon Mar. 14 at 12:42 PM
$SYBX low float ticker? Any life detected here?
0 · Reply
MoCoHai
MoCoHai Feb. 12 at 7:42 PM
$SYBX das hier ist ein no Brainer pick, korrekt? Läuft nicht so, wa?!?
0 · Reply
Brentmcneil
Brentmcneil Jan. 6 at 3:34 PM
$SYBX bullish
0 · Reply
Mrvandepol
Mrvandepol Dec. 11 at 8:46 PM
$SYBX
0 · Reply
PharmaExpert
PharmaExpert Dec. 11 at 5:49 PM
$AKBA, $CADL, $MBRX, $SYBX, $LXRX 🔥🔥🔥🔥🔥
0 · Reply
NVDAMillionaire
NVDAMillionaire Dec. 5 at 4:10 AM
$SYBX Synlogic, Inc. (SYBX): Pioneering Novel Therapies to Transform Disease Care https://beyondspx.com/article/synlogic-inc-sybx-pioneering-novel-therapies-to-transform-disease-care
0 · Reply
insiderbuyingselling
insiderbuyingselling Oct. 31 at 2:18 AM
$SYBX new insider selling: 79 shares. http://insiderbuyingselling.com/?t=SYBX
0 · Reply